Patents Assigned to Cephalon, Inc.
  • Thio-substituted arylmethanesulfinyl derivatives
    Patent number: 8071604
    Abstract: The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions of compounds of Formula (A): wherein Ar, X, Y, R1, R2, R3, and q are as defined herein; and their use in the treatment of diseases, including treatment of sleepiness, promotion of wakefulness, treatment of Parkinson's disease, cerebral ischemia, stroke, sleep apneas, eating disorders, stimulation of appetite and weight gain, treatment of attention deficit hyperactivity disorder (“ADHD”), enhancing function in disorders associated with hypofunctionality of the cerebral cortex, including, but not limited to, depression, schizophrenia, fatigue, in particular, fatigue associated with neurologic disease, such as multiple sclerosis, chronic fatigue syndrome, and improvement of cognitive dysfunction.
    Type: Grant
    Filed: November 8, 2007
    Date of Patent: December 6, 2011
    Assignees: Cephalon France, Cephalon, Inc.
    Inventors: Brigitte Lesur, Philippe Louvet, Rabindranath Tripathy
  • Pyridazinone Derivatives
    Publication number: 20110288075
    Abstract: The present invention is directed to novel pyridazinone derivatives that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition/cognitive disorders.
    Type: Application
    Filed: August 3, 2011
    Publication date: November 24, 2011
    Applicant: CEPHALON, INC.
    Inventors: Edward R. Bacon, Thomas R. Bailey, Nadine C. Becknell, Sankar Chatterjee, Derek Dunn, Greg A. Hostetler, Robert L. Hudkins, Kurt A. Josef, Lars J.S. Knutsen, Ming Tao, Allison L. Zulli
  • Proteasome inhibitors and methods of using the same
    Patent number: 8058262
    Abstract: The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity.
    Type: Grant
    Filed: February 3, 2011
    Date of Patent: November 15, 2011
    Assignee: Cephalon, Inc.
    Inventors: Raffaella Bernardini, Alberto Bernareggi, Paolo G. Cassara, Sankar Chatterjee, Germano D'Arasmo, Sergio De Munari, Edmondo Ferretti, Mohamed Iqbal, Ernesto Menta, Patricia A. Messina McLaughlin, Ambrogio Oliva
  • Fused pyrrolocarbazoles
    Patent number: 8044064
    Abstract: The present invention relates generally to selected fused pyrrolocarbazoles, including pharmaceutical compositions thereof and methods of treating diseases therewith. The present invention is also directed to intermediates and processes for making these fused pyrrolocarbazoles.
    Type: Grant
    Filed: February 18, 2010
    Date of Patent: October 25, 2011
    Assignee: Cephalon, Inc.
    Inventors: Nadine C. Becknell, Bruce A. Ruggeri, Peter D. Brown, Robert L. Hudkins, Allison L. Zulli
  • Novel Forms of a Fused Pyrrolocarbazole Compound
    Publication number: 20110230508
    Abstract: Alternative chemical and/or solid state forms of Compound I, processes to reproducibly make them and methods of treating patients using them.
    Type: Application
    Filed: May 11, 2011
    Publication date: September 22, 2011
    Applicant: CEPHALON, INC.
    Inventors: Stephen Bierlmaier, Laurent Courvoisier, Raymond Scott Field, R. Curtis Haltiwanger, Martin J. Jacobs, Robert E. McKean, Mehran Yazdanian, Veronique Courvoisier
  • ORAL TRANSMUCOSAL NICOTINE DOSAGE FORM
    Publication number: 20110206621
    Abstract: The invention described herein relates to an oral transmucosal solid dosage form useful in treating nicotine addiction or as a nicotine substitute or replacement. By virtue of the formulation in combination with nicotine, the invention transmucosally delivers an effective amount of nicotine to the recipient while permitting the accomplishing of such, and manufacture of such, using a relatively small, convenient and orally comfortable dosage form (e.g., tablet) size.
    Type: Application
    Filed: January 11, 2011
    Publication date: August 25, 2011
    Applicants: Cephalon, Inc., CIMA LABS INC.
    Inventors: Vikas Agarwal, Brian I. Hague, Rajendra K. Khankari
  • MODAFINIL FORMULATIONS
    Publication number: 20110206744
    Abstract: The invention provides an oral pharmaceutical composition comprising modafinil particles, wherein at least about 5% of said modafinil particles have a diameter greater than 200 microns.
    Type: Application
    Filed: April 29, 2011
    Publication date: August 25, 2011
    Applicant: CEPHALON, INC.
    Inventors: Moshe Bentolila, Aldo Shusterman, Moshe Arkin, Joseph Kaspi
  • Transmucosal Treatment Methods in Patients With Mucositis
    Publication number: 20110195996
    Abstract: In accordance with the invention is an fentanyl-containing dosage form designed for transmucosal delivery which includes both an effervescent couple and a pH adjusting substance which can be administered to patients suffering from both pain and mucositis. Also provided is a method of treating pain in a patient having mild oral mucositis by administering a fentanyl-containing dosage form designed for transmucosal delivery.
    Type: Application
    Filed: April 19, 2011
    Publication date: August 11, 2011
    Applicant: CEPHALON, INC.
    Inventors: Mona Darwish, Philmore Robertson, JR.
  • LIQUID FORMULATIONS OF BENDAMUSTINE
    Publication number: 20110190363
    Abstract: Stable liquid formulations of bendamustine, and pharmaceutically acceptable salts thereof, and polar aprotic solvents, are described.
    Type: Application
    Filed: March 15, 2011
    Publication date: August 4, 2011
    Applicant: CEPHALON, INC.
    Inventors: Anthony S. Drager, Rachel Y. LaBell, Piyush R. Patel
  • Processes for the Preparation of Bendamustine
    Publication number: 20110190509
    Abstract: New methods for the preparation of bendamustine, and the pharmaceutical salts thereof, are described. Novel compounds useful for the preparation of bendamustine are also described.
    Type: Application
    Filed: April 5, 2011
    Publication date: August 4, 2011
    Applicant: Cephalon, Inc.
    Inventors: Jian Chen, Katrin Przyuski, Renee Caroline Roemmele
  • Thio-substituted biarylmethanesulfinyl derivatives
    Patent number: 7981907
    Abstract: The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions that include substituted biaryl-methanesulfinyl acetamides of Formula (I): wherein Ar, Y, R1, R2, R4, R5, q and x are as defined herein; and their use in the treatment of diseases, including treatment of sleepiness associated with narcolepsy, obstructive sleep apnea, or shift work disorder; Parkinson's disease; Alzheimer's disease; attention deficit disorder; attention deficit hyperactivity disorder; depression; or fatigue associated with a neurological disease; as well as the promotion of wakefulness.
    Type: Grant
    Filed: August 27, 2008
    Date of Patent: July 19, 2011
    Assignees: Cephalon, Inc., Cephalon France
    Inventors: Edward R. Bacon, Sankar Chatterjee, Derek Dunn, Marie-Edith Gourdel, Greg Hostetler, Mohamed Iqbal, Brigitte Lesur, Philippe Louvet, Eric Riguet, Dominique Schweizer, Christophe Yue
  • PYRIDOPYRAZINES AND DERIVATIVES THEREOF AS ALK AND c-MET INHIBITORS
    Publication number: 20110160204
    Abstract: The present invention provides a compound of Formula I or a pharmaceutically acceptable salt form thereof, wherein A, L1, R1, R2, R3, R4, R5, R6, and X are as defined herein. The compounds of Formula I have ALK and/or c-Met inhibitory activity, and may be used to treat ALK- or c-Met-mediated disorders or conditions.
    Type: Application
    Filed: February 25, 2011
    Publication date: June 30, 2011
    Applicant: CEPHALON, INC.
    Inventors: Bruce D. Dorsey, Karen L. Milkiewicz, Douglas A. Pippin, Jay P. Theroff, Ted Underiner, Linda Weinberg, Craig A. Zificsak
  • Proteasome Inhibitors and Methods of Using the Same
    Publication number: 20110144033
    Abstract: The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity.
    Type: Application
    Filed: February 3, 2011
    Publication date: June 16, 2011
    Applicant: CEPHALON, INC.
    Inventors: Raffaella Bernardini, Alberto Bernareggi, Paolo G. Cassara, Sankar Chatterjee, Germano D'Arasmo, Sergio De Munari, Edmondo Ferretti, Mohamed Iqbal, Ernesto Menta, Patricia A. Messina McLaughlin, Ambrogio Oliva
  • Crystalline Forms of a Pharmaceutical Compound
    Publication number: 20110124629
    Abstract: Described are crystalline forms of the pharmaceutical compound “[9S-(9?,10?,12?)]-5,16-Bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3 -fg:3?,2?,1?-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid methyl ester”, as well as methods for their use and preparation.
    Type: Application
    Filed: January 3, 2011
    Publication date: May 26, 2011
    Applicant: CEPHALON, INC.
    Inventors: Michael Harold Rock, Heidi Lopez De Diego, Kim Lasse Christensen, Ole Nielsen, Anders Buur, Mark Howells
  • Substituted Pyridazinone Derivatives as Histamine-3 (H3) Receptor Ligands
    Publication number: 20110098269
    Abstract: The present invention provides compounds according to Formulas I, II, III, IV, V, VI, VII or VIII: their use as H3 antagonists/inverse agonists, processes for their preparation, and pharmaceutical compositions thereof.
    Type: Application
    Filed: November 17, 2010
    Publication date: April 28, 2011
    Applicant: Cephalon, Inc.
    Inventors: Nadine C. Becknell, Reddeppa reddy Dandu, Derek D. Dunn, Robert L. Hudkins, Kurt A. Josef, Babu G. Sundar, Allison L. Zulli
  • Pyridopyrazines and derivatives thereof as ALK and c-MET inhibitors
    Patent number: 7919502
    Abstract: The present invention provides a compound of Formula I or a pharmaceutically acceptable salt form thereof, wherein A, L1, R1, R2, R3, R4, R5, R6, and X are as defined herein. The compounds of Formula I have ALK and/or c-Met inhibitory activity, and may be used to treat ALK- or c-Met-mediated disorders or conditions.
    Type: Grant
    Filed: September 24, 2009
    Date of Patent: April 5, 2011
    Assignee: Cephalon, Inc.
    Inventors: Bruce D. Dorsey, Douglas A. Pippin, Jay P. Theroff, Craig A. Zificsak
  • Proteasome inhibitors and methods of using the same
    Patent number: 7915236
    Abstract: The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity.
    Type: Grant
    Filed: July 1, 2009
    Date of Patent: March 29, 2011
    Assignee: Cephalon, Inc.
    Inventors: Raffaella Bernardini, Alberto Bernareggi, Paolo G. Cassara, Sankar Chatterjee, Germano D'Arasmo, Sergio De Munari, Edmondo Ferretti, Mohamed Iqbal, Ernesto Menta, Patricia A. Messina McLaughlin, Ambrogio Oliva
  • Substituted Spirocyclic Piperidine Derivatives as Histamine-3 (H3) Receptor Ligands
    Publication number: 20110071131
    Abstract: The present invention provides compounds of Formula (I): their use as H3 antagonists/inverse agonists, processes for their preparation, and pharmaceuticals compositions thereof.
    Type: Application
    Filed: July 29, 2010
    Publication date: March 24, 2011
    Applicants: CEPHALON, INC., PHARMACOPEIA, INC.
    Inventors: Edward R. Bacon, Nadine C. Becknell, Reddeppa reddy Dandu, Lisa Guise-Zawacki, Tao Guo, Chia-yu Huang, Robert L. Hudkins, Babu G. Sundar, Ming Tao, Minglang Wu, Allison L. Zulli
  • NOVEL MULTICYCLIC COMPOUNDS AND THE USE THEREOF
    Publication number: 20110059959
    Abstract: The present invention is directed to novel multicyclic molecules that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of PARP, VEGFR2, and MLK3 enzymes, including, for example, neurodegenerative diseases, inflammation, ischemia, and cancer.
    Type: Application
    Filed: November 18, 2010
    Publication date: March 10, 2011
    Applicant: CEPHALON, INC.
    Inventors: Sankar Chatterjee, James L. Diebold, Derek Dunn, Robert L. Hudkins, Reddeppareddy Dandu, Gregory J. Wells, Allison L. Zulli
  • SUBSTITUTED BICYCLIC PYRIMIDINES
    Publication number: 20110053920
    Abstract: The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions that include substituted heterobicyclic pyrimidines of Formula (I): wherein R1, R2, R3, R4, R5, X, W, and ring A are as defined herein; pharmaceutical compositions of substituted heterobicyclic pyrimidines of Formula (I); and their use in the treatment of chronic neurodegenerative diseases, neurotraumatic diseases, depression and/or diabetes. More particularly, the present invention relates to substituted pyrazolopyrimidines of Formula (I).
    Type: Application
    Filed: November 4, 2010
    Publication date: March 3, 2011
    Applicant: CEPHALON, INC.
    Inventors: Edward R. Bacon, Thomas Bailey, Nadine C. Becknell, Diane E. Gingrich, Greg Hostetler, Robert L. Hudkins, Keith S. Learn, Jason C. Wagner